2022
Quantitative Echocardiographic Assessment and Optimal Criteria for Early Intervention in Asymptomatic Tricuspid Regurgitation
Akintoye E, Wang T, Nakhla M, Ali A, Fava A, Akyuz K, Popovic Z, Pettersson G, Gillinov A, Xu B, Griffin B, Desai M. Quantitative Echocardiographic Assessment and Optimal Criteria for Early Intervention in Asymptomatic Tricuspid Regurgitation. JACC Cardiovascular Imaging 2022, 16: 13-24. PMID: 36274042, DOI: 10.1016/j.jcmg.2022.08.004.Peer-Reviewed Original ResearchConceptsTricuspid regurgitationMedian survival timeRisk factorsAsymptomatic patientsEchocardiographic parametersSurvival timeEarly interventionOptimal timingRight heart parametersSymptomatic tricuspid regurgitationSignificant tricuspid regurgitationFree wall strainHigh operative mortalitySex-matched cohortQuantitative echocardiographic assessmentKey prognostic markersCause mortalityOperative mortalityTR patientsEchocardiographic assessmentLate presentationPoor outcomePrognostic utilityPrognostic valuePrognostic marker
2003
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
Buzdar A, O’Shaughnessy J, Booser DJ, Pippen JE, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. Journal Of Clinical Oncology 2003, 21: 1007-14. PMID: 12637464, DOI: 10.1200/jco.2003.06.108.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug Resistance, NeoplasmEndometriumEstrogen Receptor ModulatorsFemaleHumansMiddle AgedPatient SelectionPiperidinesReceptors, EstrogenSurvival AnalysisTamoxifenThiophenesTreatment OutcomeConceptsMetastatic breast cancerClinical benefit rateBreast cancerTamoxifen refractoryTR patientsResponse rateDose levelsEnd pointSelective estrogen receptor modulatorsPhase II studyPrimary end pointSecondary end pointsTumor response rateDouble-blind studyEstrogen receptor statusMetastatic disease sitesEstrogen receptor modulatorsTreatment of TSSimilar TTPTamoxifen therapyII studyDaily doseLonger TTPReceptor statusDose-dependent toxicity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply